Search results for "Intraocular"

showing 10 items of 447 documents

Genome-wide analysis of multi-ancestry cohorts identifies new loci influencing intraocular pressure and susceptibility to glaucoma

2014

Elevated intraocular pressure (IOP) is an important risk factor in developing glaucoma, and variability in IOP might herald glaucomatous development or progression. We report the results of a genome-wide association study meta-analysis of 18 population cohorts from the International Glaucoma Genetics Consortium (IGGC), comprising 35,296 multi-ancestry participants for IOP. We confirm genetic association of known loci for IOP and primary open-angle glaucoma (POAG) and identify four new IOP-associated loci located on chromosome 3q25.31 within the FNDC3B gene (P = 4.19 x 10(-8) for rs6445055), two on chromosome 9 (P = 2.80 x 10(-11) for rs2472493 near ABCA1 and P = 6.39 x 10(-11) for rs8176693…

MaleIntraocular pressuregenetic structuresGlaucomaGenome-wide association studyCohort Studies0302 clinical medicinePolymorphism (computer science)Risk FactorsPOPULATIONGeneticsAged 80 and overRISK0303 health scienceseducation.field_of_studyCOMMON VARIANTSASSOCIATIONMiddle AgedFemaleTRIALChromosomes Human Pair 3OPEN-ANGLE GLAUCOMAChromosomes Human Pair 9Glaucoma Open-AngleATP Binding Cassette Transporter 1AdultEXPRESSIONmedicine.medical_specialtyOpen angle glaucomaGenotypePopulationChromosome 9BiologyPolymorphism Single NucleotideArticleABO Blood-Group System03 medical and health sciencesYoung AdultMeta-Analysis as TopicOphthalmologyGeneticsmedicineHumansGenetic Predisposition to DiseaseeducationCENTRAL CORNEAL THICKNESSIntraocular PressureMETAANALYSIS030304 developmental biologyGenetic associationAgedChromosomes Human Pair 11Glaucomamedicine.diseaseeye diseasesFibronectinsREDUCTIONGenetic Loci030221 ophthalmology & optometrysense organsGenome-Wide Association StudyNature Genetics
researchProduct

Changes in ocular signs and symptoms in patients switching from bimatoprost-timolol to tafluprost-timolol eye drops: an open-label phase IV study.

2019

ObjectivesBimatoprost–timolol (bimatoprost 0.03%–timolol 0.5% fixed-dose combination [FDC]) and tafluprost–timolol (tafluprost 0.0015%–timolol 0.5% FDC) eye drops are currently the only topical intraocular pressure (IOP)-reducing therapies available as preservative-free (PF) prostaglandin and timolol FDC. The aim of this study was to investigate changes to ocular signs and symptoms when patients with ocular hypertension (OH) or open-angle glaucoma (OAG) switched from PF or benzalkonium chloride (BAK)-preserved bimatoprost–timolol to PF tafluprost–timolol eye drops.DesignThis was a 12-week, open-label, phase IV study.SettingSixteen centres in Finland, Germany, Italy and the UK.ParticipantsPa…

MaleIntraocular pressuregenetic structuresOcular hypertensionGlaucomaTimololBenzalkonium chloride0302 clinical medicine1506clinical pharmacology; clinical trials; glaucoma; intraocular pressure; medical ophthalmology; ocular surface; Medicine (all)Aged 80 and overintegumentary systemMedicine (all)General MedicineMiddle AgedIntention to Treat AnalysisDrug Combinations030220 oncology & carcinogenesisTimololFemaleGlaucoma Open-Anglemedicine.drug1718Adultmedicine.medical_specialtyDrug Administration Schedule03 medical and health sciencesOphthalmologymedicineHumansAntihypertensive AgentsIntraocular PressureAgedclinical trialsocular surfaceBimatoprostbusiness.industryResearchPreservatives PharmaceuticalProstaglandins FTafluprostmedicine.diseaseeye diseasesmedical ophthalmologyClinical trialOphthalmologyBimatoprostglaucoma030221 ophthalmology & optometryQuality of LifeOcular Hypertensionsense organsclinical pharmacologyOphthalmic SolutionsbusinessBMJ open
researchProduct

Hemin, an inducer of heme oxygenase-1, lowers intraocular pressure in rabbits.

2007

Carbon monoxide (CO) generated from heme may induce vasodilation and exert cyto-protective properties in the eye. This study was undertaken to investigate the effects of hemin, a potent inducer of heme oxygenase-1 (HO-1), on models of ocular hypertension in rabbits.Ocular hypertension was induced by injecting alpha-chymotrypsin in both eyes under local anesthesia. Only rabbits with an intraocular pressure (IOP) of 25 mmHg or more were used. The dose-response study of the hemin effect on IOP was made by an intravenous injection of the drug (50, 75, and 100 mg/kg) and subsequent IOP monitoring every 6 h. A separate set of animals was pretreated with the HO-1 inhibitor, zinc protoporphyrin-IX …

MaleIntraocular pressuregenetic structuresmedicine.drug_classOcular hypertensionProtoporphyrinsVasodilationPharmacologyBetamethasonechemistry.chemical_compoundRandom AllocationmedicineAnimalsChymotrypsinPharmacology (medical)Enzyme inducerIntraocular PressurePharmacologyAnalysis of VariancebiologyDose-Response Relationship Drugmedicine.diseaseeye diseasesHeme oxygenaseOphthalmologyDisease Models AnimalchemistryAnesthesiaEnzyme InductionInjections Intravenousbiology.proteinCorticosteroidBetamethasoneHeminOcular Hypertensionsense organsRabbitsHeme Oxygenase-1Heminmedicine.drugJournal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics
researchProduct

Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication.

2010

. Purpose:  The purpose of this study was to investigate the tolerability and intraocular pressure (IOP) reducing effect of the first preservative-free prostaglandin tafluprost (Taflotan®) in patients exhibiting ocular surface side-effects during latanoprost (Xalatan®) treatment. Methods:  A total of 158 patients were enrolled in this open-label multicentre study. Eligible patients had to have at least two ocular symptoms, or one sign and one symptom, during treatment with latanoprost. At baseline, the patients were directly switched from latanoprost to preservative-free tafluprost for 12 weeks. The patients were queried for ocular symptoms, and ocular signs were assessed by using tear brea…

MaleIntraocular pressuregenetic structuresmedicine.medical_treatmentAdministration TopicalMucin 5ACmedicine.disease_causeExfoliation SyndromeConjunctival Diseaseschemistry.chemical_compoundSurveys and QuestionnairesMedicineLatanoprostAged 80 and overBlepharitisGeneral MedicineMiddle AgedTolerabilityPatient SatisfactionAnesthesiaProstaglandins F SyntheticLatanoprostFemalemedicine.symptomIrritationBenzalkonium CompoundsGlaucoma Open-Anglemedicine.drugAdultGonioscopyHyperemiaTonometry OcularHumansBlepharitisAntihypertensive AgentsIntraocular PressureAgedGlaucoma medicationbusiness.industryPreservatives PharmaceuticalProstaglandins FTafluprostHLA-DR Antigensmedicine.diseaseeye diseasesOphthalmoscopyOphthalmologychemistryQuality of LifeItchingOcular Hypertensionsense organsbusinessActa ophthalmologica
researchProduct

European study of the efficacy of a cross-linked gel stent for the treatment of glaucoma

2020

indexation en cours.; PURPOSE: This study investigated the efficacy and safety of a cross-linked collagen stent (XEN 45) with or without cataract surgery in the treatment of glaucoma. SETTING: Real-life setting. DESIGN: Prospective, open-label, multicenter clinical trial. METHODS: Eligible patients with glaucoma inadequately controlled by treatment, or poor compliance or intolerance to topical therapy were included. Patients were divided into those with implant only (solo group; phakic and pseudophakic patients) and implant combined with cataract surgery (combo group). Differences in average intraocular pressure (IOP) and number of medications between baseline and study end (12 months), and…

MaleIntraocular pressuregenetic structuresmedicine.medical_treatmentVisual AcuityGlaucomasurgery0302 clinical medicineLens Implantation IntraocularimplantationProspective StudiesGlaucoma Drainage ImplantsAged 80 and overDry needlingMiddle AgedSensory Systems3. Good healthEuropeTreatment OutcomeFemaleStentsGlaucoma Open-Anglesafetymedicine.medical_specialtyintraocular-pressurepredictive-value03 medical and health sciencesTonometry OcularmedicineHumans[SDV.MHEP.OS]Life Sciences [q-bio]/Human health and pathology/Sensory OrganssuccessIntraocular PressureAgedbusiness.industryStentPhacoemulsificationCataract surgerymedicine.diseaseeye diseasesSurgeryClinical trialOphthalmologyphacoemulsification030221 ophthalmology & optometryImplantsense organsbusiness030217 neurology & neurosurgery[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyFollow-Up Studies
researchProduct

Effect of bicycle ergometer test on intraocular pressure in elderly athletes and controls.

2009

To evaluate the effect of intensive physical exercise on intraocular pressure (IOP) in 66- to 85-year-old subjects IOP was measured before and after a maximal bicycle ergometer test. The non-glaucomatous subjects comprised 85 males and 36 female athletes and 16 male and 22 female controls of corresponding age drawn from a population register. IOP was measured using a non-contact tonometer. The results indicated a decrease (> or = 2 mmHg) in 34% of the subjects, no change in 57% and an increase in 9%. The decrease was more pronounced in subjects with higher pre-test values. In all four subjects with a pre-test value above 22 mmHg a reduction from 4 to 11 mmHg was observed. The change in IOP …

MaleIntraocular pressuremedicine.medical_specialtyAginggenetic structuresPhysical ExertionGlaucomaPhysical exerciseElectrocardiographyRandom AllocationMedicineHumansIntraocular PressureAgedAged 80 and overbiologybusiness.industryAthletesGeneral Medicinemedicine.diseasebiology.organism_classificationeye diseasesTest (assessment)Intensity (physics)OphthalmologyAnesthesiaPhysical therapyExercise TestFemalesense organsBicycle ergometerbusinessPopulation RegisterGlaucoma Open-AngleSportsActa ophthalmologica
researchProduct

Randomized Trial of Brinzolamide/Brimonidine Versus Brinzolamide Plus Brimonidine for Open-Angle Glaucoma or Ocular Hypertension

2014

Introduction Fixed-combination intraocular pressure (IOP)—lowering medications simplify treatment regimens for patients requiring 2 ocular hypotensive agents to maintain sufficiently low IOP. The aim of this study was to evaluate the safety and efficacy of fixed-combination brinzolamide 1%/brimonidine 0.2% (BBFC) versus concomitant administration of brinzolamide 1% plus brimonidine 0.2% (BRINZ + BRIM) in patients with open-angle glaucoma or ocular hypertension. Methods This was a prospective, phase 3, multicenter, double-masked, 6-month trial. Patients who had insufficient IOP control with monotherapy or who were receiving 2 IOP-lowering medications were randomized 1:1 to receive twice-dail…

MaleIntraocular pressuremedicine.medical_specialtyConcomitantgenetic structuresIntraocular pressureBrinzolamideThiazinesOcular hypertensionGlaucomaOcular hypertensionlaw.inventionTonometry OcularRandomized controlled trialDouble-Blind MethodlawOphthalmologyQuinoxalinesConcomitant TherapyMedicineHumansPharmacology (medical)Fixed combinationCarbonic anhydrase inhibitorAntihypertensive AgentsOriginal ResearchAgedMedicine(all)Sulfonamidesbusiness.industryBrimonidineAlpha-2 agonistSimbrinza®GlaucomaGeneral MedicineMiddle Agedmedicine.diseaseeye diseasesDysgeusiaOphthalmologyDrug CombinationsTreatment OutcomeBrimonidine TartrateFemalesense organsmedicine.symptombusinessGlaucoma Open-Anglemedicine.drugAdvances in Therapy
researchProduct

Posterior‐chamber phakic implantable collamer lenses with a central port: a review

2020

Abstract We aimed to summarize the outcomes reported following the implantation of the V4c implantable collamer lens with a central port (ICL, STAAR Surgical Inc) for myopia correction. A literature search in PubMed, Web of Science and Scopus was carried out to identify publications reporting clinical outcomes of patients who were implanted with the V4c ICL model and had a follow‐up period of at least 6 months. A total of 35 clinical studies published between 2012 and 2020 were included in the present review. A comprehensive analysis of the available data was performed, focusing on visual and refractive outcomes at different time‐points post‐surgery. In addition, adverse events and other pa…

MaleIntraocular pressuremedicine.medical_specialtyPhakic Intraocular LensesVisual acuityWeb of sciencevisual acuityReview ArticleRefraction Ocular03 medical and health sciences0302 clinical medicinePort (medical)vaultLens Implantation IntraocularOphthalmologymedicineMyopiaphakicHumansReview ArticlesIntraocular PressureImplantable collamer lensrefractionbusiness.industryimplantable collamer lensGeneral Medicineadverse eventsEndothelial cell densityOphthalmology030221 ophthalmology & optometryFemalemedicine.symptombusiness030217 neurology & neurosurgeryActa Ophthalmologica
researchProduct

Deep sclerectomy versus trabeculectomy with low-dosage mitomycin C: four-year follow-up

2006

<i>Aims:</i> To compare the long-term effects of low-dosage mitomycin C (MMC) in both deep sclerectomy (DSMMC) and trabeculectomy (TPMMC) on intraocular pressure (IOP). <i>Methods:</i> Analysis of extended follow-up of data from a prospective clinical trial. Forty patients were originally randomised to undergo either DSMMC (19 eyes) or TPMMC (21 eyes). Follow-up was performed at postoperative day 1, weeks 1, 2 and 3, as well as months 1, 3, 6, 9, 12, 18, 24, 36 and 48. Two- to three-week data were not included in the statistical analysis. Postoperative complications, number of antiglaucoma medications and IOP were recorded at each visit. Complete (no medications) and…

MaleIntraocular pressuremedicine.medical_specialtygenetic structuresMitomycinmedicine.medical_treatmentEye diseaseGlaucomaKaplan-Meier EstimateExfoliation Syndromelaw.inventionPostoperative ComplicationsRandomized controlled triallawOphthalmologyGlaucoma surgerymedicineHumansTrabeculectomyIntraocular PressureAgedmitomycin CIntraoperative CareDose-Response Relationship Drugbusiness.industrySettore MED/30 - Malattie Apparato VisivoMitomycin Ctrabeculectomydeep sclerectomyclinical trialGeneral MedicineMiddle Agedmedicine.diseaseeye diseasesSensory SystemsSurgeryClinical trialOphthalmologyTreatment OutcomeSclerostomyFemalesense organsbusinessGlaucoma Open-AngleFollow-Up Studies
researchProduct

E-PTFE (Gore-Tex) implant with or without low-dosage mitomycin-C as an adjuvant in penetrating glaucoma surgery: 2 year randomized clinical trial.

2008

Purpose: To test the expanded polytetrafluoroethylene (ePTFE) as a new adjuvant in trabeculectomy. Methods: Consecutive glaucoma surgical inpatients were observed at the Department of Ophthalmology of Palermo University. Sixty patients (60 eyes) were randomly assigned to undergo trabeculectomy (T), trabeculectomy with mitomycin-C (TMMC), with ePTFE (TG) or with mitomycin-C and ePTFE (TGMMC). Postoperative visits were scheduled at 24 hr, 7 days, 1, 3, 6, 12, 18 and 24 months. Complete success and qualified success were assessed at two target intraocular pressure (IOP) levels – £21 and £17 mmHg – by Kaplan–Meier curves. Results: The postoperative IOP reduction was significant (P < 0.01) at th…

MaleIntraocular pressuremedicine.medical_specialtygenetic structuresmedicine.medical_treatmentMitomycinGlaucomaOcular HypotensionTrabeculectomyKaplan-Meier Estimatelaw.inventionRandomized controlled triallawpenetrating glaucoma surgerymedicineGlaucoma surgeryTrabeculectomyHumansPostoperative PeriodSurvival ratePolytetrafluoroethyleneIntraocular PressureE-PTFE (Gore-Tex)implantAgedDose-Response Relationship Drugbusiness.industryMitomycin CGlaucomaGeneral MedicineProstheses and ImplantsMiddle Agedmedicine.diseaserandomized clinical trialSurgerylow-dosage mitomycin-Cpenetrating glaucoma surgery; E-PTFE (Gore-Tex)implant; low-dosage mitomycin-C; randomized clinical trialOphthalmologyChemotherapy AdjuvantAnesthesiaFemaleImplantbusiness
researchProduct